Trump Obamacare deal could pave way for end to individual mandate

29 November 2017

American lawmakers meeting in a closed-door session reportedly received assurances from President Trump that he would be willing to support measures that would bolster the wobbling Obamacare exchange markets, in return for an end to the individual mandate.

Republican senator Lindsey Graham, a vocal opponent of the Affordable Care Act, reported after the meeting that Mr Trump said: “If the tax bill passes with an individual mandate repeal he would” give his support.

However, any attempt to end the individual mandate via the tax reform legislation currently under discussion would face opposition from Democrats.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK